Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Whitehawk Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
20.2
0
14
14
15.2
24.4
26
7.15
Cost of revenue
0
1.34
2.81
3.02
0.76
Gross profit
14
13.9
21.5
23
6.39
Research and development
11.4
12.1
17.9
12.8
15
19.7
32.7
48.9
51
91
Selling, general and administrative
18.5
40.2
44.5
36.7
29.8
General and administrative
5.27
9.24
13.5
9.76
2.12
18.5
Operating expenses
16.6
21.4
31.3
24.4
17.1
112
Operating income
-16.6
-21.4
-11.2
-24.4
-2.55
-111
-62.7
-71.9
-67.5
-114
Interest expense
0.01
0.82
0.67
0.23
0.23
0.15
0
Interest income
0.04
0.01
2.4
6.4
3.93
6.23
Other non-operating income
-0.35
-0.01
0.78
1.17
2.04
1.13
2.17
6.17
3.77
93.8
Pre-tax income
-3.48
-110
-60.5
-65.8
-63.7
-20.6
Income tax
0
0
0
0
0
0
Net income
-17
-21.4
-10.4
-23.3
-3.48
-110
-60.5
-65.8
-63.7
-20.6
EBITDA
-16.6
-21.3
-11.1
-24.4
-2.54
-111
-62.5
-71.8
-67.3
-114
EPS, basic
-431.55
-18.13
-5.46
-10.03
-1.76
-12.41
-2.69
-2.44
-2.36
-0.33
EPS, diluted
-431.55
-18.13
-5.46
-10.03
-1.76
-12.41
-2.69
-2.44
-2.36
-0.33
Shares, basic (weighted)
0.05
1.23
1.93
2.31
2.54
8.92
22.5
26.9
27
61.9
Shares, diluted (weighted)
0.05
1.23
1.93
2.31
2.54
8.92
22.5
26.9
27
61.9
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
1.61
20.3
62.6
38.5
4.46
149
39
62.9
28.7
37.6
Short-term investments
0.05
0
134
46
18.6
108
Receivables
0
14.1
0
1.86
5.49
5.9
0
Inventory
0
1.86
6.43
5.31
0
Other current assets
0.21
0.32
0.62
0.73
1.6
2.28
3.75
3.83
2.84
3.32
Total current assets
2.23
20.9
64
39.6
18.7
151
180
125
61.3
149
Property, plant and equipment
0.15
0.11
0.1
0.16
0.02
0.06
0.51
4.8
6.85
0
Lease right-of-use assets
0.16
0.12
0.56
1.52
1.17
0.79
0
Intangible assets
0
3.81
0
Other non-current assets
2.21
2.18
1.87
1.4
1.81
Total assets
2.4
21
64.1
39.9
18.8
158
184
132
70.3
151
Accounts payable
1.14
1.28
0.6
0.44
2.39
6.44
3.52
5.9
2.16
0.92
Accrued liabilities
0.01
4.1
8.7
14.9
14.3
14.6
13.6
Total current liabilities
14.9
3.59
5.46
3.33
30.1
15.3
18.8
26.4
17.1
14.5
Lease liabilities
0.07
0.47
1.27
0.83
0.57
0
Other non-current liabilities
0.1
0
0
0.2
0
Total liabilities
88.6
3.59
5.46
3.4
31.3
21.5
25.9
27.2
17.8
14.5
Paid-in capital
0.05
126
178
179
20.2
279
362
374
385
489
Retained earnings
-86.2
-109
-119
-142
-32.6
-143
-203
-269
-333
-353
Other comprehensive income
0
-0.12
0.03
0.02
0.12
Shareholders' equity
-86.2
17.4
58.7
-9.09
-12.4
136
158
105
52.5
136
Total equity
-86.2
17.4
58.7
-9.09
-12.4
136
158
105
52.5
136
Total liabilities and equity
2.4
21
64.1
39.9
18.8
158
184
132
70.3
151
Shares outstanding
0.07
1.54
2.31
2.31
2.54
20.9
24.4
24.6
24.7
47.1
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-17
-21.4
-10.4
-23.3
-3.48
-110
-60.5
-65.8
-63.7
-20.6
Depreciation and amortization
0.07
0.05
0.05
0.08
0.01
0.11
0.16
0.17
0.19
0.08
Stock-based compensation
0.49
0.65
3.43
1.09
0.14
2.11
9.64
12
10.8
9.87
Deferred income tax
0
0
0
0
0
0
Change in receivables
0.11
0
-13.9
14.1
-1.86
-3.63
-0.42
-1
Change in inventory
0
-1.86
-3.27
1.12
0.17
Change in payables
0
1.6
1.86
-2.22
1.08
8.29
3.22
-0.13
-9.77
3.92
Cash from operations
-0.02
-18.9
-5.81
-23.9
-12.7
-22.4
-49.6
-59.7
-59.6
-97.4
Capital expenditures
-0.11
-0.01
-0.04
-0.24
-0.02
-0.05
-0.44
-3.97
-1.65
-0.55
Purchases of investments
0
-145
-64.4
-36.5
-149
Cash from investing
-0.11
0.04
-0.04
-0.24
-0.02
25.2
-133
83.2
25.2
11.9
Stock issued
0.02
40.2
51.6
9.74
155
0
0.08
0
0.03
Dividends paid
-4.41
0
Cash from financing
0.01
37.5
48.2
1.19
142
72.6
0.33
0.13
94.4
Net change in cash
-3.53
18.7
42.3
-24.1
-11.5
145
-110
23.9
-34.2
8.83
Free cash flow
-0.14
-18.9
-5.85
-24.1
-12.7
-22.5
-50.1
-63.6
-61.2
-98
Interest paid
0.02
0.23
0.23
0.21
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $3.74 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-43.6%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-41.2%
Net income / average total assets.
Return on invested capital (ROIC)
-69.6%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-72.5%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-22.3%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-12.6%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
-72.2%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-22.8%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
159.7%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-4.9%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
114.5%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-6.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
51.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
129.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
40.1%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
89.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
17.4x
Current assets / current liabilities.
Quick ratio
17.2x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
17.2x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.00
Revenue / diluted weighted shares.
FCF per share
-$0.84
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.84
Cash from operations / diluted weighted shares.
Book value per share
$3.21
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
1.17x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.17x
Market cap / tangible book value, when positive.
FCF yield
-32.5%
Free cash flow / market cap.
Earnings yield
-37.4%
Net income / market cap (the inverse of P/E).
What was Whitehawk Therapeutics, Inc.'s revenue in fiscal 2025?
Whitehawk Therapeutics, Inc. reported revenue of $7.1M for fiscal 2025, 72.5% lower than the year before.
Was Whitehawk Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $20.6M.
How much free cash flow did Whitehawk Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $97.4M minus capital expenditures of $552.0K left free cash flow of -$98.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.